Articles tagged with Drug Therapy
Researchers at CNIO have identified a protein, CDC25A, as a determinant of chemotherapy resistance in cancer cells. They used CRISPR genome editing technology to test various mutations and found that cells with this mutation were resistant to treatment.
The ATMOSPHERE trial found aliskiren alone or in combination with enalapril had no significant benefit on mortality and hospitalization rates in patients with heart failure. However, adding aliskiren increased the risk of symptoms like low blood pressure and elevated potassium levels.
A new study reveals that only 1.02% of eligible patients receive weight loss medications, highlighting a significant gap between guidelines and treatment practices.
Researchers apply global sensitivity analysis to pinpoint key HIV model parameters affecting treatment plans. By fixing non-influential inputs and minimizing parameter dimensions, they better understand HIV dynamics and develop optimal treatment strategies.
The Endocrine Society recommends a multidisciplinary approach to diabetes care, emphasizing the need for coordinated care teams and comprehensive services. The Society advocates for policy changes and increased funding to address gaps in knowledge and promote innovative treatments.
Researchers aim to collect and analyze 100,000 TB samples to create a database of MDR-TB genes, enabling faster diagnosis using whole genome sequencing. The project, CRyPTIC, will take around five years to complete and could potentially save lives by providing the right treatment.
Researchers at IBS created a wearable GP-based patch that allows accurate diabetes monitoring and feedback therapy using human sweat. The device enables systematic corrections of sweat glucose measurements by monitoring pH and temperature, reducing the need for painful treatments like insulin shots.
Researchers have identified promising biomarkers to monitor immunosuppressive drug therapy in organ transplant recipients, with the potential for individualized treatment to reduce rejection and minimize side effects. A panel of experts recommends a preliminary set of tests for use in biomarker-based immunosuppressive drug management.
A Cancer Research UK-funded study suggests an HIV drug could block the molecular switch that boosts cells' ability to survive treatment, making treatments more potent and delaying drug resistance. The research, carried out in mice, implies that nelfinavir could be used to combat melanoma skin cancers.
A new digital 'map' detailing different mechanisms contributing to asthma development could help researchers redefine the disease. The AsthmaMap allows personalized treatment by targeting specific asthma subgroups.
A University of Florida study found that less than one-quarter of patients with prediabetes received treatment from their primary care physician. Prediabetes is a common condition that increases the risk of vascular problems and diabetes, yet many people remain undiagnosed or untreated.
The review discusses conventional immunosuppressive agents and biologic therapies, including rituximab and belimumab, as effective treatments for refractory SLE. Managing co-morbidities like cardiovascular risk factors and bone health is also crucial in SLE treatment.
A new study is exploring whether the drug Omalizumab can be targeted at specific patients with severe asthma, who are expected to benefit most from the treatment. This research aims to identify biomarkers that will enable more effective treatment and improve symptoms for those suffering from severe asthma.
A two-year clinical trial found that Eylea (aflibercept) performed better than Avastin (bevacizumab) in participants with moderate or worse vision loss, while Lucentis (ranibizumab) yielded similar gains. The study confirmed the effectiveness of all three drugs for diabetic macular edema treatment.
The Patient Empowered Precision Medicine Alliance (PEPMA) aims to rapidly match patients with the right drugs for their condition. The project leverages University-derived technologies to determine whether existing drugs can be repurposed to treat rare conditions.
A recent study published in the BMJ found that intensive blood pressure lowering treatment using antihypertensive drugs may increase the risk of cardiovascular death in people with diabetes and systolic blood pressure levels under 140 mm Hg. However, for those with high blood pressure, treatment is crucial to prevent complications.
Researchers develop adaptive therapy that adjusts drug dose based on tumor response, controlling growth and allowing 60-80% of mice to be weaned off the drug. The treatment approach stabilizes tumors by maintaining a small population of drug-sensitive cells to suppress resistant cell growth.
Researchers at Dana-Farber Cancer Institute propose securitized consumer healthcare loans to spread the cost of therapies over many years, making them more accessible to patients. This approach aims to generate attractive returns to investors while providing affordable access to life-saving drugs and cures.
Researchers found that Retigabine enhances the resting potential open state stability of K7.2/K7.3 channels, increasing potassium ion flow and decreasing electrical signals. This may help refine pharmacotherapy for epilepsy and related disorders.
Women with asthma experienced a significantly longer median total time to pregnancy (32.2 months vs 55.6 months) compared to those without asthma. Additionally, the birth rate was lower among asthmatic women, with fewer successful conceptions (39.6% vs 60.4%).
Researchers develop small molecule inhibitor to address hypertrophic cardiomyopathy, a common cause of sudden death in young athletes. The treatment has shown promising results in mice bred with the mutation, preventing the disease from surfacing.
Researchers at NIH/NIEHS discovered that increasing tristetraprolin (TTP) levels in mice significantly reduced or protected against inflammation. TTP may offer an effective treatment for inflammatory diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Researchers demonstrate MYK-461's ability to prevent and reverse hypertrophic cardiomyopathy (HCM) in genetically modified mouse models. The study supports a therapeutic hypothesis that reducing sarcomere power output can improve structural pathology, potentially treating HCM.
A record-breaking number of new drugs were approved last year, including biologics for rare diseases and cancer treatments. However, the high costs of these therapies pose a significant challenge for patients and the pharmaceutical industry.
A study published in JAMA found that dupilumab improves nasal polyp symptoms and quality of life in patients with chronic sinusitis not responsive to corticosteroids. The medication was generally well-tolerated and showed significant improvements in endoscopic, clinical, and radiographic outcomes after 16 weeks.
Dasatinib, a cancer treatment, reduces inflammation and improves lung mechanics in mice with allergic asthma. The drug targets tyrosine kinases involved in asthma's signaling pathways.
Experts have issued a framework to guide difficult prioritization decisions among children in need of scarce life-saving chemotherapy treatment. The modified utilitarian model maximizes total benefit from available supply, considering factors like curability, prognosis, and drug importance.
Researchers at LMU Munich uncover the mechanism by which crystalline deposits induce cell death, revealing a regulated process leading to necroptosis and inflammation. This discovery offers new targets for therapies and potentially improves treatment of conditions like gout and atherosclerosis.
A new scientific statement highlights differences in heart attacks between women and men, including different underlying causes, symptoms, and risk factors. Women are more likely to have atypical symptoms and undertreated with guideline-recommended medications, leading to worse outcomes.
A new scientific statement from the American Heart Association underscores the need to understand and treat heart disease in women. Women's hearts are different from men's, with unique symptoms such as palpitations, back pain, or jaw pain, which can be misdiagnosed due to lack of awareness.
A new report by a Task Force of the American Society for Bone and Mineral Research suggests that clinicians should reassess osteoporosis medication use after 5 years. Periodic evaluation and monitoring are key to weighing benefits and risks.
A Swedish study found that psoriasis patients over 30 years old are 65% less likely to receive efficient treatment with biologics. Researchers analyzed health data from 1,465 patients and controlled for variables such as gender, BMI, and comorbidity.
Researchers have designed controlled release microspheres to reduce the number of doses needed for patients with pulmonary arterial hypertension. The innovative treatment provides a convenient alternative to current therapies, which require frequent inhalation.
New research reveals that many adolescents with asthma do not have elevated levels of eosinophils or neutrophils, which are typically associated with inflammation. This finding has significant implications for the development of alternative treatments for asthmatics.
A landmark Phase II study by Winship Cancer Institute led to the approval of daratumumab for multiple myeloma patients who have received at least three prior treatments. The drug showed an overall response rate of nearly 30% and demonstrated single-agent activity in a novel monoclonal antibody treatment.
The International Osteoporosis Foundation is urging physicians to individualize treatment decisions based on patients' fracture risk, rather than automatically interrupting or stopping bisphosphonate therapy. The benefits of continued therapy in high-risk patients greatly exceed the risk of rare side effects.
The Concise Guide to PHARMACOLOGY 2015/2016 provides an overview of 1,700 human drug targets, focusing on those exploited in the clinic or with future therapeutic potential. The guide combines evidence-based data with summaries of molecular targets, allowing users to rapidly gain insight into their function and comparative pharmacology.
A prospective cohort study found that receiving an average of at least six potentially effective drugs per day was associated with a 36% greater likelihood of responding to treatment. The inclusion of more drugs, particularly pyrazinamide, was also linked to improved sputum culture conversion rates.
Delays in restoring blood flow after a stroke were associated with decreased benefits of intra-arterial clot-busting treatment and reduced chances for a good outcome. The chances for a good outcome were reduced by 6 percent for every hour of reperfusion delay.
A study of 30 patients found that surgery effectively controlled hypercalcemia, normalized parathyroid hormone levels, and improved bone density. In contrast, medication only controlled excess calcium in 67% of cases, with no effect on PTH or slowing the decline in bone density.
A new study published in Biological Psychiatry reports the successful reduction of fear in spider-fearful participants following a 2-minute exposure combined with a single dose of propranolol. The treatment resulted in drastically reduced avoidance behavior and increased approach behavior, with effects persisting for one year.
A new study found that black patients receiving Medicare are less likely to receive biologic therapies for moderate to severe psoriasis than white patients, while those without low-income subsidy are also at a disadvantage. Psoriasis, a chronic inflammatory disorder, has limited therapeutic options due to high costs and limited insuran...
Researchers are exploring the use of ketone esters to treat seizures caused by hyperbaric oxygen toxicity in deep-water divers. Laboratory rats showed improved performance and greater resistance to oxygen toxicity seizures after receiving the dose.
A new study suggests that pomaglumetad methionil, a glutamate pathway target, may be an effective treatment for individuals in the early course of schizophrenia. Researchers found a statistically significant response in patients who are early-in-disease or have not already been exposed to other antipsychotic medications.
A new study published in Annals of Oncology shows that abiraterone acetate is effective in treating aggressive prostate cancers, even those with high Gleason scores. The treatment extended progression-free survival by up to 16.5 months in patients previously treated with docetaxel.
A new approach calculates an objective probability of treatment effectiveness, potentially revealing up to 20% of older treatments were mistakenly labelled as ineffective. Researchers may be dismissing treatments with small degrees of effectiveness due to flawed evaluation methods.
A recent study found that two-thirds of studies on 'psychosocial' treatments list co-authors who financially benefit from the treatments, yet few declare a conflict of interest. This lack of transparency may lead to biased research and influenced policy decisions.
The University of Kentucky has received $6 million in funding to further develop a potential treatment for cocaine abuse. The project, led by Professor Chang-Guo Zhan, aims to create a novel enzyme that can neutralize cocaine in the bloodstream using molecular modeling technology.
Researchers develop nanoparticles that can carry therapeutics across the brain blood barrier, offering new hope for treating glioblastoma multiforme. The 3HM nanocarriers show promising attributes for treating brain cancers.
Researchers have found that a commonly used Type II diabetes medication can effectively clear fatty liver disease from some patients. After a 48-week trial, 4 out of 10 patients showed significant improvement in non-alcoholic steatohepatitis symptoms.
A new UCL study of 77,045 dementia patients across the UK found that those from more affluent areas are 27% more likely to be prescribed anti-dementia drugs. This inequality was not seen in Scotland, Northern Ireland, or Wales.
A new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism found that Viagra improves insulin sensitivity in individuals with prediabetes. The medication also reduces a biological marker that signals heightened risk of kidney and heart disease.
Researchers have discovered a new mechanism of drug resistance in metastatic prostate cancer cells, which can be predicted using protein levels. The study found that high levels of 4EBP1 protein lead to decreased protein synthesis and resistance to PI3K pathway inhibitors.
Classifying high risk has become a disease in itself, undermining preventive medicine efforts. Doctors and patients often lack understanding of what constitutes high risk and the anticipated treatment benefit, leading to ineffective prevention strategies.
A new study suggests that intravitreous ranibizumab injections may be a reasonable treatment alternative to panretinal photocoagulation (PRP) at least through 2 years for patients with proliferative diabetic retinopathy. The study found that ranibizumab met noninferiority outcomes in visual acuity change compared to PRP.
Researchers found that adding exposure and response prevention therapy to treatment regimens significantly improved symptoms in patients with OCD who had not responded to medication. The study also showed significant increases in insight, quality of life, and social function after just eight weeks.
Treatment with anti-angiogenesis drugs improves radiation treatment of nervous system tumors in animal models, reducing tumor size and nerve damage. Anti-VEGF treatment enhances nerve regeneration and decreases muscle atrophy.
A new study published in Annals of Behavioral Medicine suggests that behavioral interventions can lead to significant improvements in cardiovascular health. The research indicates that small behavioral changes can have a substantial impact on physical health outcomes.
A new study published in the American Journal of Psychiatry suggests that cognitive-behavioral therapy (CBT) is more effective than light therapy in preventing relapse of seasonal affective disorder (SAD). CBT was found to be significantly better at preventing depression recurrence, with only 27% of subjects experiencing symptoms compa...
Researchers have developed a radiotherapeutic bandage that has shown promise as an alternative therapy for squamous cell carcinoma (SCC) in an animal model. The bandages, which are made with nanoparticles containing inactivated radioactive material, can be individually tailored and manufactured on a large scale.